RecruitingNot Applicable

Brain PERfusion Evaluation by Contrast-Enhanced UltraSound

France60 participantsStarted 2023-07-21

Plain-language summary

The objective of the study is to assess brain tissue perfusion by contrast-enhanced ultrasound perfusion imaging (PerCEUS) in acute brain injuries. More precisely, it aims : * to evaluate the heterogeneity of brain perfusion and thus diagnose brain tissue hypoperfusion with contrast-enhanced ultrasound. * to correlate contrast-enhanced ultrasound with perfusion measurements by usual multimodal monitoring.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 * Intensive care unit admission for acute brain injury * Proven acute brain injury by CT and/or MRI * Requiring a contrast ultrasound imaging * Informed consent of patient or relative Exclusion Criteria: * Pregnancy * Not sufficient temporal window * Contraindications to Sonovue ® : acute coronary syndromes, severe ischemic heart disease (requiring revascularization), pulmonary arterial hypertension \> 90 mmHg, right-left shunt, ARDS, dobutamine's use, known allergy or adverse reaction to Sonovue® * Patient on State Medical Assistance

What they're measuring

Evaluation of the heterogeneity of brain perfusion by time-to-peak (TPI) measurement

Timeframe: 30 minutes after PerCEUS

Evaluation of the heterogeneity of brain perfusion by peak-intensities (PI) measurement

Timeframe: 30 minutes after PerCEUS

Trial details

NCT IDNCT05893407

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07

Contact for this trial

Romain BARTHELEMY, MD

+33 (0)1 49 95 85 15 romain.barthelemy@aphp.fr

View on ClinicalTrials.gov More Cerebral Hemorrhage trials